Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| First-in-human Study of S-588210 (S-488210+S-488211) |
| completed |
| Phase 1 |
| 10 |
| ShionogiINDUSTRY |
| 1 |
| Jan 26, 2022 |
| clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 27 | Halozyme TherapeuticsINDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04601766 | A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets | completed | Phase 1 | 12 | Asieris Pharmaceuticals (AUS) Pty Ltd.INDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT00003930 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | completed | Phase 1 / Phase 2 | 84 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 20, 2020 | clinicaltrials |
| NCT02092948 | Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer | completed | Phase 1 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02720367 | Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer | completed | Phase 1 | 12 | Taris Biomedical LLCINDUSTRY | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00005858 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | completed | Phase 1 | 25 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02300610 | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | completed | Phase 1 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT01844947 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract(VINSOR) | completed | Phase 1 | 22 | Dr Anders UllénOTHER | 2 | Apr 26, 2019 | clinicaltrials |
| NCT01259063 | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | completed | Phase 1 / Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01090466 | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 1 / Phase 2 | 15 | Cardiff UniversityOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02852564 | Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | completed | Phase 1 | 12 | Eugene Lee, MDOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT00004095 | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 38 | Northwestern UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01162785 | 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer | completed | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01182168 | Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00652210 | Use of Multiphoton Microscopy in the Diagnosis of Cancer(MPM) | completed | Phase 1 | 344 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT02437539 | Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography(uPAR-PET) | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Aug 24, 2015 | clinicaltrials |
| NCT00556621 | Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer(GEMCIRAV) | completed | Phase 1 / Phase 2 | 14 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00082719 | Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
| NCT00019435 | LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT01498172 | BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | completed | Phase 1 | 23 | Patrice JichlinskiOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT01087697 | Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit | completed | Phase 1 | 8 | TengionINDUSTRY | 1 | Dec 10, 2014 | clinicaltrials |
| NCT00544609 | Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent(SOGUG-07-01) | completed | Phase 1 | 10 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT00313599 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | University of California, San FranciscoOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00623064 | Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 1 | 18 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 1, 2014 | clinicaltrials |
| NCT00016237 | Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment | completed | Phase 1 | — | EMD SeronoINDUSTRY | 1 | Oct 23, 2013 | clinicaltrials |
| NCT01939756 | Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms(Baobab) | completed | Phase 1 / Phase 2 | 50 | Savino M. Di StasiOTHER | 1 | Sep 11, 2013 | clinicaltrials |
| NCT00002949 | Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | completed | Phase 1 | 33 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00014456 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00003103 | Chemotherapy in Treating Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00003105 | Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer | completed | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00003342 | Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer | completed | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00003133 | Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer | completed | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 28, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 14, 2022source: clinicaltrials